Transforming Severe Asthma Care: New Perspectives on IL5 and Beyond

One CME point pending

28th March 2025

CLICK HERE
To register

ONLINE
1 - 2 pm

Time	Topic	Presenter
13:00 – 13:05	Welcome & introduction	Dr. Tay Tunn Ren
13:05 – 13:10	T2 inflammation in Severe Asthma	Prof. Peter Gibson
13:10 – 13:15	Emerging science: Role of IL-5 beyond Eosinophils	Prof. Peter Gibson
13:15 – 13:20	Clinical case: Severe Asthma & CRSwNP co-morbid	Prof. Peter Gibson
13:20 – 13:30	Long-term goal of Severe Asthma management	Prof. Peter Gibson
13:30 – 13:45	Local clinical case sharing & discussion	Dr. Tay Tunn Ren
13:45 – 14:00	Q&A and closing	Dr. Tay Tunn Ren

Chair & Faculty



Dr. Tay Tunn Ren
MBBS, MRCP (UK), FAMS
Senior Consultant,
Changi General Hospital

Faculty



Prof. Peter Gibson
FRACP, FThorSoc, DMed (Research)
Conjoint Professor, University of Newcastle; Respiratory Specialist, John Hunter Hospital, Newcastle, Australia

Under the auspices of

SINGAPORE THORACIC SOCIETY

For Singapore Healthcare Professionals Only
All images used in this material are for illustration purposes only
GSK is not responsible for third party website content.
For reporting of adverse events please write to sg.drugsafety@gsk.com
Trademarks are owned by or licensed to the GSK group of companies
© 2025 GSK group of companies or its licensor.
GlaxoSmithKline Pte Ltd, 23 Rochester Park, Singapore 139234
PM-SG-MPL-AGND-250001 | March 2025

NUCALA
mepolizumab

Scan for full NUCALA PI

*Nucala is indicated as add-on maintenance treatment of severe eosinophilic asthma in patients 12 years and older.